Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchial anti-inflammatory effect of augmentation therapy in alpha-1 antitrypsin deficiency
2008-001962-94Phase 4Active
- Sponsor
- Marc Miravitlles
- Start
- May 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Marc Miravitlles. Primary endpoints: Steady-state alpha-1 antitrypsin concentration in serum, Steady-state alpha-1 antitrypsin concentration in bronchial secretions and 3 more. Started May 2008; status: active.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2008-001962-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001962-94.